Specifically, reduction of PMS2 protein levels was found to be associated with temozolomide resistance, and inactivating mutations of MSH6 gene and loss of MSH6 function have been associated with emergent temozolomide resistance in GBM patients [40, 41]. Here, MSH6 is linked to glioblastoma.